Market Outlook
The global Sickle Cell Anemia Therapeutics market size was valued at USD 3440.8 million in 2022 and is forecast to a readjusted size of USD 9166.5 million by 2029 with a CAGR of 15.0% during review period.
Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglobin known as sickle hemoglobin (HbS).
Global Sickle Cell Anemia Therapeutics key players include Emmaus Medical, Addmedica, Gamida Cell, GlycoMimetics, etc. Americas is the largest market, with a share about 55%, followed by Europe, and Middle East & Africa, both have a share over 35 percent. In terms of product, Blood Transfusion is the largest segment, with a share over 35%. And in terms of application, the largest application is Child, followed by adult.
This report is a detailed and comprehensive analysis for global Sickle Cell Anemia Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Sickle Cell Anemia Therapeutics market size and forecasts, in consumption value ($ Million), 2018-2029
Global Sickle Cell Anemia Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Sickle Cell Anemia Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Sickle Cell Anemia Therapeutics market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Sickle Cell Anemia Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Sickle Cell Anemia Therapeutics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Key Market Players
Emmaus Medical
Addmedica
Gamida Cell
GlycoMimetics
Pfizer
Novartis
Global Blood Therapeutics
Micelle BioPharma
Bluebird Bio
Prolong Pharmaceuticals
Modus Therapeutics
Sangamo Biosciences
Bioverativ
Imara
Ironwood Pharmaceuticals
Segmentation By Type
Blood Transfusion
Pharmacotherapy
Bone Marrow Transplant
Segmentation By Application
Child
Adult
Segmentation By Region
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Market SWOT Analysis
What are the strengths of the Sickle Cell Anemia Therapeutics Market 2025?
The increasing awareness and advancements in gene therapy and CRISPR technology offer promising treatment options. Additionally, the growing number of FDA-approved drugs for managing sickle cell disease provides more options for patients, improving market growth potential.
What are the weaknesses of the Sickle Cell Anemia Therapeutics Market 2025?
High treatment costs and the limited availability of specialized healthcare facilities for sickle cell management could hinder market growth. Also, the challenge of accessibility in low-income regions may limit the reach of emerging therapies.
What are the opportunities in the Sickle Cell Anemia Therapeutics Market 2025?
There is significant potential in expanding research and clinical trials focused on gene editing and novel drug therapies. Partnerships between biotech companies and healthcare providers may improve treatment delivery and access, especially in developing regions.
What are the threats to the Sickle Cell Anemia Therapeutics Market 2025?
The market faces the risk of regulatory hurdles delaying the approval of new therapies. Additionally, competition from alternative treatments and the possibility of market saturation as more options become available could slow down overall growth.
Market PESTEL Analysis
What are the political factors affecting the Sickle Cell Anemia Therapeutics Market 2025?
Government funding and policies promoting research into rare diseases, including sickle cell anemia, are crucial. Policy changes in healthcare reimbursement models and drug pricing regulations will also impact the affordability and accessibility of treatments.
What are the economic factors influencing the Sickle Cell Anemia Therapeutics Market 2025?
High treatment costs, especially for advanced gene therapies, can create economic barriers for patients, especially in lower-income regions. However, economic growth in emerging markets may increase access to innovative treatments and drive demand for therapeutic options.
What are the social factors shaping the Sickle Cell Anemia Therapeutics Market 2025?
Social awareness campaigns and advocacy for sickle cell anemia have increased, pushing for better care and more research. The growing focus on genetic counseling and personalized medicine also impacts public acceptance and the adoption of new therapies.
What are the technological factors impacting the Sickle Cell Anemia Therapeutics Market 2025?
Breakthroughs in gene therapy, such as CRISPR-Cas9, are revolutionizing treatment options, with a focus on potentially curative therapies. Advancements in drug delivery systems and diagnostic tools will improve patient outcomes and treatment management.
What are the environmental factors affecting the Sickle Cell Anemia Therapeutics Market 2025?
Sickle cell treatments often require specific storage conditions, such as temperature control, which could present logistical challenges in some regions. Environmental sustainability concerns related to the production and disposal of medical products also play a role in the industry.
What are the legal factors influencing the Sickle Cell Anemia Therapeutics Market 2025?
Regulatory frameworks and patent laws significantly influence the development and commercialization of new treatments. Intellectual property protections around gene-editing technologies and drug formulations are also crucial in shaping market dynamics and competition.
Market SIPOC Analysis
Who are the suppliers in the Sickle Cell Anemia Therapeutics Market 2025?
Suppliers include pharmaceutical companies, biotech firms, research institutions, and raw material providers for drug production. These entities provide the necessary materials, technologies, and innovations that drive the development of therapies.
What are the inputs for the Sickle Cell Anemia Therapeutics Market 2025?
The inputs consist of advanced biotechnology, genetic research, clinical trials, regulatory approvals, and healthcare infrastructure. These elements are crucial for creating new therapeutic options and making them accessible to patients.
What are the processes involved in the Sickle Cell Anemia Therapeutics Market 2025?
The processes include drug development, clinical trials, regulatory approval, marketing, distribution, and patient education. Ongoing research and partnerships also play a critical role in advancing and refining treatments for sickle cell anemia.
What are the outputs of the Sickle Cell Anemia Therapeutics Market 2025?
The outputs include FDA-approved drugs, gene therapies, treatment protocols, and educational resources for patients and healthcare providers. The ultimate goal is to provide effective, affordable therapies for the management and potential cure of sickle cell anemia.
Who are the customers in the Sickle Cell Anemia Therapeutics Market 2025?
Customers are primarily healthcare providers, including hospitals, clinics, and specialized treatment centers. Additionally, patients with sickle cell anemia, along with caregivers and advocacy groups, are key participants in the therapeutic process.
Market Porter's Five Forces
What is the threat of new entrants in the Sickle Cell Anemia Therapeutics Market 2025?
The threat is moderate, as entering the market requires substantial investment in research, development, and clinical trials. Additionally, the regulatory barriers and need for specialized expertise in gene therapy and rare diseases limit new players from easily entering the market.
What is the bargaining power of suppliers in the Sickle Cell Anemia Therapeutics Market 2025?
The bargaining power of suppliers is high, as the market relies on specialized biotech companies, research institutions, and raw material providers. Limited sources for certain advanced technologies and materials in gene therapy increase their leverage in negotiations.
What is the bargaining power of buyers in the Sickle Cell Anemia Therapeutics Market 2025?
The bargaining power of buyers is relatively low due to the specialized and limited nature of available treatments for sickle cell anemia. With a small number of approved therapies and few alternatives, patients and healthcare providers have less influence over pricing and availability.
What is the threat of substitute products in the Sickle Cell Anemia Therapeutics Market 2025?
The threat of substitutes is low, as there are limited alternative treatment options available. Although palliative care methods exist, there are no direct substitutes for the innovative gene therapies or FDA-approved drugs being developed to treat or potentially cure sickle cell anemia.
What is the intensity of competitive rivalry in the Sickle Cell Anemia Therapeutics Market 2025?
The competitive rivalry is moderate to high, as there are several established pharmaceutical and biotech companies focused on sickle cell anemia therapeutics. However, the market is still developing, and while competition exists, the number of effective treatments remains limited, leading to both innovation and collaboration.
Market Upstream Analysis
What are the key suppliers in the Sickle Cell Anemia Therapeutics Market 2025?
Key suppliers include biotechnology firms, pharmaceutical companies, research institutions, and raw material providers. These entities supply the essential technologies, biologics, and genetic materials required for the development of novel therapies.
What resources are necessary for the Sickle Cell Anemia Therapeutics Market 2025?
The resources required include advanced gene-editing technologies, specialized equipment for clinical trials, skilled labor, and raw materials for drug manufacturing. Additionally, substantial funding and access to clinical data are essential to drive innovation.
What are the main activities involved in the upstream process of the Sickle Cell Anemia Therapeutics Market 2025?
The main activities include research and development, clinical trials, securing regulatory approvals, and manufacturing. Collaboration between research institutions and pharmaceutical companies is also critical in advancing therapeutic solutions for sickle cell anemia.
What challenges are faced in the upstream process of the Sickle Cell Anemia Therapeutics Market 2025?
Challenges include the high costs of R&D, regulatory approval delays, and the technical complexities of gene therapies. Limited access to expertise and specialized facilities also poses challenges in developing effective treatments at scale.
What are the trends influencing the upstream process in the Sickle Cell Anemia Therapeutics Market 2025?
Emerging trends include advancements in gene therapy, particularly CRISPR-based technologies, and increased collaboration between biotech companies and academic research centers. There's also a growing focus on precision medicine and personalized treatment approaches for sickle cell anemia.
Market Midstream Analysis
What are the key activities in the midstream process of the Sickle Cell Anemia Therapeutics Market 2025?
The key activities include drug formulation, clinical testing, obtaining regulatory approvals, and scaling up manufacturing. Collaboration with healthcare providers and monitoring the efficacy of treatments through clinical trials are also vital components.
What are the challenges in the midstream process of the Sickle Cell Anemia Therapeutics Market 2025?
Challenges include the high cost of clinical trials, navigating complex regulatory requirements, and ensuring that new treatments are scalable for large patient populations. Additionally, delays in securing market approval or unforeseen adverse effects during trials can disrupt the process.
What role do healthcare providers play in the midstream process of the Sickle Cell Anemia Therapeutics Market 2025?
Healthcare providers are critical in administering clinical trials, collecting patient data, and offering feedback on treatment effectiveness. They also serve as important partners in educating patients and ensuring the successful adoption of new therapies.
What technologies are being utilized in the midstream process of the Sickle Cell Anemia Therapeutics Market 2025?
Technologies such as gene editing (e.g., CRISPR), cell therapy, and advanced drug delivery systems are being utilized to optimize treatment effectiveness. Additionally, real-time monitoring tools and data analytics are being used to track patient outcomes and refine therapies.
What are the trends influencing the midstream process in the Sickle Cell Anemia Therapeutics Market 2025?
Key trends include the rise of personalized medicine and the shift towards more targeted therapies. The integration of digital health solutions to monitor treatment progress and the growing emphasis on gene therapies for potentially curative treatments are also influencing the midstream process.
Market Downstream Analysis
What are the key activities in the downstream process of the Sickle Cell Anemia Therapeutics Market 2025?
Key activities include the distribution and marketing of approved therapies, post-market surveillance, patient education, and providing ongoing support through healthcare systems. Ensuring proper patient access to treatments through partnerships with insurance providers is also crucial.
What are the challenges in the downstream process of the Sickle Cell Anemia Therapeutics Market 2025?
Challenges include the high cost of treatments limiting patient access, especially in lower-income regions. Additionally, distribution logistics, particularly in underdeveloped areas, and ensuring long-term efficacy of treatments can be difficult.
How do healthcare providers impact the downstream process of the Sickle Cell Anemia Therapeutics Market 2025?
Healthcare providers play a central role in the downstream process by administering therapies, monitoring patient outcomes, and providing essential support to ensure adherence to treatment regimens. They are also integral to educating patients on the benefits and side effects of treatments.
What technologies are being used in the downstream process of the Sickle Cell Anemia Therapeutics Market 2025?
Technologies such as electronic health records (EHR), telemedicine platforms, and patient monitoring systems are increasingly being used for better treatment tracking and management. These technologies help in ensuring continuity of care and improving patient compliance.
What are the trends influencing the downstream process in the Sickle Cell Anemia Therapeutics Market 2025?
Emerging trends include the shift toward personalized medicine, where treatments are tailored to individual genetic profiles, and the growing use of digital health tools to improve patient engagement. The increasing emphasis on long-term management and follow-up care is also influencing downstream strategies.
Chapter 1, to describe Sickle Cell Anemia Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Sickle Cell Anemia Therapeutics, with revenue, gross margin and global market share of Sickle Cell Anemia Therapeutics from 2018 to 2023.
Chapter 3, the Sickle Cell Anemia Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Sickle Cell Anemia Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Sickle Cell Anemia Therapeutics.
Chapter 13, to describe Sickle Cell Anemia Therapeutics research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Sickle Cell Anemia Therapeutics
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Sickle Cell Anemia Therapeutics by Type
1.3.1 Overview: Global Sickle Cell Anemia Therapeutics Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Sickle Cell Anemia Therapeutics Consumption Value Market Share by Type in 2022
1.3.3 Blood Transfusion
1.3.4 Pharmacotherapy
1.3.5 Bone Marrow Transplant
1.4 Global Sickle Cell Anemia Therapeutics Market by Application
1.4.1 Overview: Global Sickle Cell Anemia Therapeutics Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Child
1.4.3 Adult
1.5 Global Sickle Cell Anemia Therapeutics Market Size & Forecast
1.6 Global Sickle Cell Anemia Therapeutics Market Size and Forecast by Region
1.6.1 Global Sickle Cell Anemia Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Sickle Cell Anemia Therapeutics Market Size by Region, (2018-2029)
1.6.3 North America Sickle Cell Anemia Therapeutics Market Size and Prospect (2018-2029)
1.6.4 Europe Sickle Cell Anemia Therapeutics Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Sickle Cell Anemia Therapeutics Market Size and Prospect (2018-2029)
1.6.6 South America Sickle Cell Anemia Therapeutics Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Sickle Cell Anemia Therapeutics Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Emmaus Medical
2.1.1 Emmaus Medical Details
2.1.2 Emmaus Medical Major Business
2.1.3 Emmaus Medical Sickle Cell Anemia Therapeutics Product and Solutions
2.1.4 Emmaus Medical Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Emmaus Medical Recent Developments and Future Plans
2.2 Addmedica
2.2.1 Addmedica Details
2.2.2 Addmedica Major Business
2.2.3 Addmedica Sickle Cell Anemia Therapeutics Product and Solutions
2.2.4 Addmedica Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Addmedica Recent Developments and Future Plans
2.3 Gamida Cell
2.3.1 Gamida Cell Details
2.3.2 Gamida Cell Major Business
2.3.3 Gamida Cell Sickle Cell Anemia Therapeutics Product and Solutions
2.3.4 Gamida Cell Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Gamida Cell Recent Developments and Future Plans
2.4 GlycoMimetics
2.4.1 GlycoMimetics Details
2.4.2 GlycoMimetics Major Business
2.4.3 GlycoMimetics Sickle Cell Anemia Therapeutics Product and Solutions
2.4.4 GlycoMimetics Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 GlycoMimetics Recent Developments and Future Plans
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business
2.5.3 Pfizer Sickle Cell Anemia Therapeutics Product and Solutions
2.5.4 Pfizer Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Pfizer Recent Developments and Future Plans
2.6 Novartis
2.6.1 Novartis Details
2.6.2 Novartis Major Business
2.6.3 Novartis Sickle Cell Anemia Therapeutics Product and Solutions
2.6.4 Novartis Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Novartis Recent Developments and Future Plans
2.7 Global Blood Therapeutics
2.7.1 Global Blood Therapeutics Details
2.7.2 Global Blood Therapeutics Major Business
2.7.3 Global Blood Therapeutics Sickle Cell Anemia Therapeutics Product and Solutions
2.7.4 Global Blood Therapeutics Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Global Blood Therapeutics Recent Developments and Future Plans
2.8 Micelle BioPharma
2.8.1 Micelle BioPharma Details
2.8.2 Micelle BioPharma Major Business
2.8.3 Micelle BioPharma Sickle Cell Anemia Therapeutics Product and Solutions
2.8.4 Micelle BioPharma Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Micelle BioPharma Recent Developments and Future Plans
2.9 Bluebird Bio
2.9.1 Bluebird Bio Details
2.9.2 Bluebird Bio Major Business
2.9.3 Bluebird Bio Sickle Cell Anemia Therapeutics Product and Solutions
2.9.4 Bluebird Bio Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Bluebird Bio Recent Developments and Future Plans
2.10 Prolong Pharmaceuticals
2.10.1 Prolong Pharmaceuticals Details
2.10.2 Prolong Pharmaceuticals Major Business
2.10.3 Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Product and Solutions
2.10.4 Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Prolong Pharmaceuticals Recent Developments and Future Plans
2.11 Modus Therapeutics
2.11.1 Modus Therapeutics Details
2.11.2 Modus Therapeutics Major Business
2.11.3 Modus Therapeutics Sickle Cell Anemia Therapeutics Product and Solutions
2.11.4 Modus Therapeutics Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Modus Therapeutics Recent Developments and Future Plans
2.12 Sangamo Biosciences
2.12.1 Sangamo Biosciences Details
2.12.2 Sangamo Biosciences Major Business
2.12.3 Sangamo Biosciences Sickle Cell Anemia Therapeutics Product and Solutions
2.12.4 Sangamo Biosciences Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Sangamo Biosciences Recent Developments and Future Plans
2.13 Bioverativ
2.13.1 Bioverativ Details
2.13.2 Bioverativ Major Business
2.13.3 Bioverativ Sickle Cell Anemia Therapeutics Product and Solutions
2.13.4 Bioverativ Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Bioverativ Recent Developments and Future Plans
2.14 Imara
2.14.1 Imara Details
2.14.2 Imara Major Business
2.14.3 Imara Sickle Cell Anemia Therapeutics Product and Solutions
2.14.4 Imara Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Imara Recent Developments and Future Plans
2.15 Ironwood Pharmaceuticals
2.15.1 Ironwood Pharmaceuticals Details
2.15.2 Ironwood Pharmaceuticals Major Business
2.15.3 Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Product and Solutions
2.15.4 Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Ironwood Pharmaceuticals Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Sickle Cell Anemia Therapeutics Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Sickle Cell Anemia Therapeutics by Company Revenue
3.2.2 Top 3 Sickle Cell Anemia Therapeutics Players Market Share in 2022
3.2.3 Top 6 Sickle Cell Anemia Therapeutics Players Market Share in 2022
3.3 Sickle Cell Anemia Therapeutics Market: Overall Company Footprint Analysis
3.3.1 Sickle Cell Anemia Therapeutics Market: Region Footprint
3.3.2 Sickle Cell Anemia Therapeutics Market: Company Product Type Footprint
3.3.3 Sickle Cell Anemia Therapeutics Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Sickle Cell Anemia Therapeutics Consumption Value and Market Share by Type (2018-2023)
4.2 Global Sickle Cell Anemia Therapeutics Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global Sickle Cell Anemia Therapeutics Consumption Value Market Share by Application (2018-2023)
5.2 Global Sickle Cell Anemia Therapeutics Market Forecast by Application (2024-2029)
6 North America
6.1 North America Sickle Cell Anemia Therapeutics Consumption Value by Type (2018-2029)
6.2 North America Sickle Cell Anemia Therapeutics Consumption Value by Application (2018-2029)
6.3 North America Sickle Cell Anemia Therapeutics Market Size by Country
6.3.1 North America Sickle Cell Anemia Therapeutics Consumption Value by Country (2018-2029)
6.3.2 United States Sickle Cell Anemia Therapeutics Market Size and Forecast (2018-2029)
6.3.3 Canada Sickle Cell Anemia Therapeutics Market Size and Forecast (2018-2029)
6.3.4 Mexico Sickle Cell Anemia Therapeutics Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe Sickle Cell Anemia Therapeutics Consumption Value by Type (2018-2029)
7.2 Europe Sickle Cell Anemia Therapeutics Consumption Value by Application (2018-2029)
7.3 Europe Sickle Cell Anemia Therapeutics Market Size by Country
7.3.1 Europe Sickle Cell Anemia Therapeutics Consumption Value by Country (2018-2029)
7.3.2 Germany Sickle Cell Anemia Therapeutics Market Size and Forecast (2018-2029)
7.3.3 France Sickle Cell Anemia Therapeutics Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Sickle Cell Anemia Therapeutics Market Size and Forecast (2018-2029)
7.3.5 Russia Sickle Cell Anemia Therapeutics Market Size and Forecast (2018-2029)
7.3.6 Italy Sickle Cell Anemia Therapeutics Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific Sickle Cell Anemia Therapeutics Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Sickle Cell Anemia Therapeutics Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Sickle Cell Anemia Therapeutics Market Size by Region
8.3.1 Asia-Pacific Sickle Cell Anemia Therapeutics Consumption Value by Region (2018-2029)
8.3.2 China Sickle Cell Anemia Therapeutics Market Size and Forecast (2018-2029)
8.3.3 Japan Sickle Cell Anemia Therapeutics Market Size and Forecast (2018-2029)
8.3.4 South Korea Sickle Cell Anemia Therapeutics Market Size and Forecast (2018-2029)
8.3.5 India Sickle Cell Anemia Therapeutics Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Sickle Cell Anemia Therapeutics Market Size and Forecast (2018-2029)
8.3.7 Australia Sickle Cell Anemia Therapeutics Market Size and Forecast (2018-2029)
9 South America
9.1 South America Sickle Cell Anemia Therapeutics Consumption Value by Type (2018-2029)
9.2 South America Sickle Cell Anemia Therapeutics Consumption Value by Application (2018-2029)
9.3 South America Sickle Cell Anemia Therapeutics Market Size by Country
9.3.1 South America Sickle Cell Anemia Therapeutics Consumption Value by Country (2018-2029)
9.3.2 Brazil Sickle Cell Anemia Therapeutics Market Size and Forecast (2018-2029)
9.3.3 Argentina Sickle Cell Anemia Therapeutics Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa Sickle Cell Anemia Therapeutics Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Sickle Cell Anemia Therapeutics Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Country
10.3.1 Middle East & Africa Sickle Cell Anemia Therapeutics Consumption Value by Country (2018-2029)
10.3.2 Turkey Sickle Cell Anemia Therapeutics Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Sickle Cell Anemia Therapeutics Market Size and Forecast (2018-2029)
10.3.4 UAE Sickle Cell Anemia Therapeutics Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 Sickle Cell Anemia Therapeutics Market Drivers
11.2 Sickle Cell Anemia Therapeutics Market Restraints
11.3 Sickle Cell Anemia Therapeutics Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 Sickle Cell Anemia Therapeutics Industry Chain
12.2 Sickle Cell Anemia Therapeutics Upstream Analysis
12.3 Sickle Cell Anemia Therapeutics Midstream Analysis
12.4 Sickle Cell Anemia Therapeutics Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global Sickle Cell Anemia Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Sickle Cell Anemia Therapeutics Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Sickle Cell Anemia Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Sickle Cell Anemia Therapeutics Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Emmaus Medical Company Information, Head Office, and Major Competitors
Table 6. Emmaus Medical Major Business
Table 7. Emmaus Medical Sickle Cell Anemia Therapeutics Product and Solutions
Table 8. Emmaus Medical Sickle Cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Emmaus Medical Recent Developments and Future Plans
Table 10. Addmedica Company Information, Head Office, and Major Competitors
Table 11. Addmedica Major Business
Table 12. Addmedica Sickle Cell Anemia Therapeutics Product and Solutions
Table 13. Addmedica Sickle Cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Addmedica Recent Developments and Future Plans
Table 15. Gamida Cell Company Information, Head Office, and Major Competitors
Table 16. Gamida Cell Major Business
Table 17. Gamida Cell Sickle Cell Anemia Therapeutics Product and Solutions
Table 18. Gamida Cell Sickle Cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Gamida Cell Recent Developments and Future Plans
Table 20. GlycoMimetics Company Information, Head Office, and Major Competitors
Table 21. GlycoMimetics Major Business
Table 22. GlycoMimetics Sickle Cell Anemia Therapeutics Product and Solutions
Table 23. GlycoMimetics Sickle Cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. GlycoMimetics Recent Developments and Future Plans
Table 25. Pfizer Company Information, Head Office, and Major Competitors
Table 26. Pfizer Major Business
Table 27. Pfizer Sickle Cell Anemia Therapeutics Product and Solutions
Table 28. Pfizer Sickle Cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Pfizer Recent Developments and Future Plans
Table 30. Novartis Company Information, Head Office, and Major Competitors
Table 31. Novartis Major Business
Table 32. Novartis Sickle Cell Anemia Therapeutics Product and Solutions
Table 33. Novartis Sickle Cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Novartis Recent Developments and Future Plans
Table 35. Global Blood Therapeutics Company Information, Head Office, and Major Competitors
Table 36. Global Blood Therapeutics Major Business
Table 37. Global Blood Therapeutics Sickle Cell Anemia Therapeutics Product and Solutions
Table 38. Global Blood Therapeutics Sickle Cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Global Blood Therapeutics Recent Developments and Future Plans
Table 40. Micelle BioPharma Company Information, Head Office, and Major Competitors
Table 41. Micelle BioPharma Major Business
Table 42. Micelle BioPharma Sickle Cell Anemia Therapeutics Product and Solutions
Table 43. Micelle BioPharma Sickle Cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Micelle BioPharma Recent Developments and Future Plans
Table 45. Bluebird Bio Company Information, Head Office, and Major Competitors
Table 46. Bluebird Bio Major Business
Table 47. Bluebird Bio Sickle Cell Anemia Therapeutics Product and Solutions
Table 48. Bluebird Bio Sickle Cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Bluebird Bio Recent Developments and Future Plans
Table 50. Prolong Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 51. Prolong Pharmaceuticals Major Business
Table 52. Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Product and Solutions
Table 53. Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Prolong Pharmaceuticals Recent Developments and Future Plans
Table 55. Modus Therapeutics Company Information, Head Office, and Major Competitors
Table 56. Modus Therapeutics Major Business
Table 57. Modus Therapeutics Sickle Cell Anemia Therapeutics Product and Solutions
Table 58. Modus Therapeutics Sickle Cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Modus Therapeutics Recent Developments and Future Plans
Table 60. Sangamo Biosciences Company Information, Head Office, and Major Competitors
Table 61. Sangamo Biosciences Major Business
Table 62. Sangamo Biosciences Sickle Cell Anemia Therapeutics Product and Solutions
Table 63. Sangamo Biosciences Sickle Cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Sangamo Biosciences Recent Developments and Future Plans
Table 65. Bioverativ Company Information, Head Office, and Major Competitors
Table 66. Bioverativ Major Business
Table 67. Bioverativ Sickle Cell Anemia Therapeutics Product and Solutions
Table 68. Bioverativ Sickle Cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. Bioverativ Recent Developments and Future Plans
Table 70. Imara Company Information, Head Office, and Major Competitors
Table 71. Imara Major Business
Table 72. Imara Sickle Cell Anemia Therapeutics Product and Solutions
Table 73. Imara Sickle Cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Imara Recent Developments and Future Plans
Table 75. Ironwood Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 76. Ironwood Pharmaceuticals Major Business
Table 77. Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Product and Solutions
Table 78. Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. Ironwood Pharmaceuticals Recent Developments and Future Plans
Table 80. Global Sickle Cell Anemia Therapeutics Revenue (USD Million) by Players (2018-2023)
Table 81. Global Sickle Cell Anemia Therapeutics Revenue Share by Players (2018-2023)
Table 82. Breakdown of Sickle Cell Anemia Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3)
Table 83. Market Position of Players in Sickle Cell Anemia Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 84. Head Office of Key Sickle Cell Anemia Therapeutics Players
Table 85. Sickle Cell Anemia Therapeutics Market: Company Product Type Footprint
Table 86. Sickle Cell Anemia Therapeutics Market: Company Product Application Footprint
Table 87. Sickle Cell Anemia Therapeutics New Market Entrants and Barriers to Market Entry
Table 88. Sickle Cell Anemia Therapeutics Mergers, Acquisition, Agreements, and Collaborations
Table 89. Global Sickle Cell Anemia Therapeutics Consumption Value (USD Million) by Type (2018-2023)
Table 90. Global Sickle Cell Anemia Therapeutics Consumption Value Share by Type (2018-2023)
Table 91. Global Sickle Cell Anemia Therapeutics Consumption Value Forecast by Type (2024-2029)
Table 92. Global Sickle Cell Anemia Therapeutics Consumption Value by Application (2018-2023)
Table 93. Global Sickle Cell Anemia Therapeutics Consumption Value Forecast by Application (2024-2029)
Table 94. North America Sickle Cell Anemia Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 95. North America Sickle Cell Anemia Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 96. North America Sickle Cell Anemia Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 97. North America Sickle Cell Anemia Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 98. North America Sickle Cell Anemia Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 99. North America Sickle Cell Anemia Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 100. Europe Sickle Cell Anemia Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 101. Europe Sickle Cell Anemia Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 102. Europe Sickle Cell Anemia Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 103. Europe Sickle Cell Anemia Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 104. Europe Sickle Cell Anemia Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 105. Europe Sickle Cell Anemia Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 106. Asia-Pacific Sickle Cell Anemia Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 107. Asia-Pacific Sickle Cell Anemia Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 108. Asia-Pacific Sickle Cell Anemia Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 109. Asia-Pacific Sickle Cell Anemia Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 110. Asia-Pacific Sickle Cell Anemia Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
Table 111. Asia-Pacific Sickle Cell Anemia Therapeutics Consumption Value by Region (2024-2029) & (USD Million)
Table 112. South America Sickle Cell Anemia Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 113. South America Sickle Cell Anemia Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 114. South America Sickle Cell Anemia Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 115. South America Sickle Cell Anemia Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 116. South America Sickle Cell Anemia Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 117. South America Sickle Cell Anemia Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 118. Middle East & Africa Sickle Cell Anemia Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 119. Middle East & Africa Sickle Cell Anemia Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 120. Middle East & Africa Sickle Cell Anemia Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 121. Middle East & Africa Sickle Cell Anemia Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 122. Middle East & Africa Sickle Cell Anemia Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 123. Middle East & Africa Sickle Cell Anemia Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 124. Sickle Cell Anemia Therapeutics Raw Material
Table 125. Key Suppliers of Sickle Cell Anemia Therapeutics Raw Materials
List of Figures
Figure 1. Sickle Cell Anemia Therapeutics Picture
Figure 2. Global Sickle Cell Anemia Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Sickle Cell Anemia Therapeutics Consumption Value Market Share by Type in 2022
Figure 4. Blood Transfusion
Figure 5. Pharmacotherapy
Figure 6. Bone Marrow Transplant
Figure 7. Global Sickle Cell Anemia Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 8. Sickle Cell Anemia Therapeutics Consumption Value Market Share by Application in 2022
Figure 9. Child Picture
Figure 10. Adult Picture
Figure 11. Global Sickle Cell Anemia Therapeutics Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 12. Global Sickle Cell Anemia Therapeutics Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 13. Global Market Sickle Cell Anemia Therapeutics Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 14. Global Sickle Cell Anemia Therapeutics Consumption Value Market Share by Region (2018-2029)
Figure 15. Global Sickle Cell Anemia Therapeutics Consumption Value Market Share by Region in 2022
Figure 16. North America Sickle Cell Anemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 17. Europe Sickle Cell Anemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 18. Asia-Pacific Sickle Cell Anemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 19. South America Sickle Cell Anemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 20. Middle East and Africa Sickle Cell Anemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 21. Global Sickle Cell Anemia Therapeutics Revenue Share by Players in 2022
Figure 22. Sickle Cell Anemia Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 23. Global Top 3 Players Sickle Cell Anemia Therapeutics Market Share in 2022
Figure 24. Global Top 6 Players Sickle Cell Anemia Therapeutics Market Share in 2022
Figure 25. Global Sickle Cell Anemia Therapeutics Consumption Value Share by Type (2018-2023)
Figure 26. Global Sickle Cell Anemia Therapeutics Market Share Forecast by Type (2024-2029)
Figure 27. Global Sickle Cell Anemia Therapeutics Consumption Value Share by Application (2018-2023)
Figure 28. Global Sickle Cell Anemia Therapeutics Market Share Forecast by Application (2024-2029)
Figure 29. North America Sickle Cell Anemia Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 30. North America Sickle Cell Anemia Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 31. North America Sickle Cell Anemia Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 32. United States Sickle Cell Anemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 33. Canada Sickle Cell Anemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 34. Mexico Sickle Cell Anemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 35. Europe Sickle Cell Anemia Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 36. Europe Sickle Cell Anemia Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 37. Europe Sickle Cell Anemia Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 38. Germany Sickle Cell Anemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 39. France Sickle Cell Anemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 40. United Kingdom Sickle Cell Anemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 41. Russia Sickle Cell Anemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 42. Italy Sickle Cell Anemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 43. Asia-Pacific Sickle Cell Anemia Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 44. Asia-Pacific Sickle Cell Anemia Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 45. Asia-Pacific Sickle Cell Anemia Therapeutics Consumption Value Market Share by Region (2018-2029)
Figure 46. China Sickle Cell Anemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 47. Japan Sickle Cell Anemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 48. South Korea Sickle Cell Anemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 49. India Sickle Cell Anemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 50. Southeast Asia Sickle Cell Anemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 51. Australia Sickle Cell Anemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 52. South America Sickle Cell Anemia Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 53. South America Sickle Cell Anemia Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 54. South America Sickle Cell Anemia Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 55. Brazil Sickle Cell Anemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 56. Argentina Sickle Cell Anemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 57. Middle East and Africa Sickle Cell Anemia Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 58. Middle East and Africa Sickle Cell Anemia Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 59. Middle East and Africa Sickle Cell Anemia Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 60. Turkey Sickle Cell Anemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 61. Saudi Arabia Sickle Cell Anemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 62. UAE Sickle Cell Anemia Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 63. Sickle Cell Anemia Therapeutics Market Drivers
Figure 64. Sickle Cell Anemia Therapeutics Market Restraints
Figure 65. Sickle Cell Anemia Therapeutics Market Trends
Figure 66. Porters Five Forces Analysis
Figure 67. Manufacturing Cost Structure Analysis of Sickle Cell Anemia Therapeutics in 2022
Figure 68. Manufacturing Process Analysis of Sickle Cell Anemia Therapeutics
Figure 69. Sickle Cell Anemia Therapeutics Industrial Chain
Figure 70. Methodology
Figure 71. Research Process and Data Source
